Burlingame, CA, United States of America

Wayne J Fairbrother

USPTO Granted Patents = 22 (Patent Applications = 8)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 6.1

ph-index = 11

Forward Citations = 386(Granted Patents)

Location History:

Burlingame, CA (US) (2000 - 2023)
South San Francisco, CA (US) (2017 - 2023)

Company Filing History:

Walter and Eliza Hall Institute of Medical Research

patents

4. 4 out of 4,945

Hoffmann-la Roche Inc.

patents

5. 2 out of 4,179

Abbott Laboratories Corporation

patents

6. 1 out of 94

The Burnham Institute

patents

7. 1 out of 168

F. Hoffmann-la Roche Ag

patents

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187816 - Macrocyclic compounds and methods of use thereof (2025-01-07),

2. 11666581 - PROTAC antibody conjugates and methods of use (2023-06-06),

3. 11590128 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2023-02-28),

4. 11413282 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2022-08-16),

5. 11110087 - Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor (2021-09-07),

6. 10993942 - Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor (2021-05-04),

7. 9539251 - Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor (2017-01-10),

8. 9067928 - Compounds and methods of use (2015-06-30),

9. 8980837 - Inhibitors of IAP (2015-03-17),

10. 8518970 - Compounds and methods of use (2013-08-27),

11. 8232273 - Heterocyclic compounds and methods of use (2012-07-31),

12. 8168645 - Arylsulfonamide compounds (2012-05-01),

13. 8114893 - Compounds and methods of use (2012-02-14),

14. 8110568 - Inhibitors of IAP (2012-02-07),

15. 7563583 - Heregulin variants (2009-07-21),

Title: Wayne J. Fairbrother: Innovator in Macrocyclic Compounds and PROTAC Technologies

Introduction

Wayne J. Fairbrother is a distinguished inventor based in Burlingame, California, recognized for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, Fairbrother's work emphasizes innovation in macrocyclic compounds and targeted protein degradation.

Latest Patents

His latest patents showcase his cutting-edge research in the pharmaceutical domain. One such innovation is titled "Macrocyclic Compounds and Methods of Use Thereof," which focuses on various applications of macrocyclic compounds. Additionally, his work on "PROTAC Antibody Conjugates and Methods of Use" explores the development of antibody-PROTAC conjugates, paving the way for new pharmaceutical compositions that target diseases where protein degradation offers therapeutic benefits.

Career Highlights

Wayne Fairbrother has had a vibrant career, working with prominent companies such as Genentech, Inc. and AbbVie Inc. His experience in these leading pharmaceutical firms has allowed him to contribute significantly to the advancement of medical science through innovative drug designs and therapies.

Collaborations

Throughout his professional journey, Fairbrother collaborated with esteemed colleagues like John A. Flygare and Frederick Cohen. These partnerships have fostered an environment of creativity and innovation, further enhancing the development of advanced therapeutic solutions.

Conclusion

Wayne J. Fairbrother stands out as a pivotal figure in the pharmaceutical industry. His inventive spirit and commitment to research continue to influence the landscape of medical treatments, making him a noteworthy inventor in macrocyclic compounds and PROTAC technologies. His work not only highlights the importance of collaboration among inventors but also underscores the role of innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.